Department of Orthopedics, Qilu Hospital of Shandong University, Jinan, China.
Orthop Surg. 2024 May;16(5):1246-1251. doi: 10.1111/os.14043. Epub 2024 Mar 31.
Percutaneous CT-guided radiofrequency ablation (CT-RFA) is a widely accepted procedure for treatment of osteoid osteomas. However, the application of CT-RFA was restricted as a result of some drawbacks, such as radiation exposure, and inconvenience in general anesthesia. The primary aim of this study is to evaluate the safety and efficacy of intra-operative TiRobot-assisted percutaneous RFA of osteoid osteomas.
We retrospectively reviewed 21 medical files of patients who were treated with percutaneous RFA of osteoid osteomas guided by the TiRobot system in our institution between March 2021 and April 2022. The three-dimensional images obtained by a 3D C-arm intra-operatively were sent to the TiRobot system. The puncture point and trajectory were designed. Then the guide pin was positioned to the lesion with the assistance of TiRobot and the biopsy sheath was inserted into the lesion through the guide pin. The tumor was biopsied for pathological examination. Then the RFA needle was inserted into the nidus through the biopsy sheath for thermal ablation. Data were extracted on the associated complications, the reduction in pain at 1 month and 1 year postoperatively assessed by the visual analogue scale (VAS). A paired t-test was used to compare the pre-operative and post-operative VAS scores.
The patients included 17 males and four females with a mean age of 19.5 ± 10.4 years (range 3-45 years). Lesions were located on the femur in nine cases, on the tibia in nine cases, on the humerus in one case, on the calcaneus in one case, and on the acetabulum in one case. TiRobot-assisted percutaneous RFA was successfully performed on all 21 patients. There was no intra-operative or post-operative complications observed. Pathological diagnosis of osteoid osteoma was obtained in 11 patients, but the other 10 cases were not pathologically diagnosed. The mean follow-up time was 18.8 months (range: 12-26 months).Post-operative VAS scores were reduced significantly in all cases. The mean VAS score decreased from 6.5 pre-operatively to 0.5 at 1 month post-operatively and to 0.1 at 1 year post-operatively.
As a reliable technique for localizing and resection of nidus, TiRobot-assisted percutaneous RFA is a safe and effective option for the treatment of osteoid osteomas.
经皮 CT 引导下射频消融术(CT-RFA)是治疗骨样骨瘤的一种广泛接受的方法。然而,由于辐射暴露和全身麻醉不便等一些缺点,CT-RFA 的应用受到限制。本研究的主要目的是评估术中 TiRobot 辅助经皮射频消融术治疗骨样骨瘤的安全性和疗效。
我们回顾性分析了 2021 年 3 月至 2022 年 4 月期间在我院接受 TiRobot 系统引导下经皮射频消融术治疗的 21 例骨样骨瘤患者的病历资料。术中通过 3D C 臂获得的三维图像发送到 TiRobot 系统,设计穿刺点和轨迹。然后在 TiRobot 的辅助下将导针定位到病灶,通过导针插入活检套管进入病灶。对肿瘤进行活检以进行病理检查。然后将 RFA 针通过活检套管插入病灶进行热消融。记录相关并发症,术后 1 个月和 1 年通过视觉模拟评分(VAS)评估疼痛缓解情况。采用配对 t 检验比较术前和术后的 VAS 评分。
患者包括 17 名男性和 4 名女性,平均年龄为 19.5±10.4 岁(3-45 岁)。病变位于股骨 9 例,胫骨 9 例,肱骨 1 例,跟骨 1 例,髋臼 1 例。21 例患者均成功完成 TiRobot 辅助经皮 RFA。术中及术后均未见并发症。11 例患者获得骨样骨瘤的病理诊断,但其余 10 例未获得病理诊断。平均随访时间为 18.8 个月(12-26 个月)。所有患者术后 VAS 评分均明显降低。术前 VAS 评分为 6.5 分,术后 1 个月降至 0.5 分,术后 1 年降至 0.1 分。
TiRobot 辅助经皮 RFA 作为一种定位和切除病灶的可靠技术,是治疗骨样骨瘤的一种安全有效的选择。